Company to present four abstracts at the American Association for Cancer Research 2025 annual meeting highlighting research from AVITI24, the Trinity™ workflow solution, and new direct in sample sequencing applications
Element Biosciences, a company democratizing access to advanced life science solutions, today announced the accelerated rollout and availability of direct in sample sequencing on AVITI24, the first intelligent multiomics system. Direct in sample sequencing, or DISS, is a high-demand and transformative technology that unlocks unprecedented research possibilities across a variety of new use cases, including lineage tracing and CRISPR screens with simultaneous optical phenotyping, targeted RNA sequencing, custom protein analysis, and more – all completely library-prep free. Direct in sample sequencing technology will be available for preorder May 21, 2025.
“Direct in sample sequencing is a leap forward that removes any and all library prep entirely, enabling scientists to profile RNA, proteins, phosphoproteins, and cell morphology from a single sample in one automated run. It opens the door to smart, scalable biology—shifting the field to high-resolution, high-value insights at unprecedented speed,” said Michael Previte, Co-founder and Chief Technology Officer of Element Biosciences.
New research from the AVITI24 platform, including abstracts and workshop sessions, will be presented at the American Association for Cancer Research (AACR) annual meeting in Chicago from April 25-30. Attendees can meet the Element team at Booth #4035 and Meeting Room MR-119.
Source – BusinessWire
Related Posts
Company to present four abstracts at the American Association for Cancer Research 2025 annual meeting highlighting research from AVITI24, the Trinity™ workflow solution, and new direct in sample sequencing applications
Element Biosciences, a company democratizing access to advanced life science solutions, today announced the accelerated rollout and availability of direct in sample sequencing on AVITI24, the first intelligent multiomics system. Direct in sample sequencing, or DISS, is a high-demand and transformative technology that unlocks unprecedented research possibilities across a variety of new use cases, including lineage tracing and CRISPR screens with simultaneous optical phenotyping, targeted RNA sequencing, custom protein analysis, and more – all completely library-prep free. Direct in sample sequencing technology will be available for preorder May 21, 2025.
“Direct in sample sequencing is a leap forward that removes any and all library prep entirely, enabling scientists to profile RNA, proteins, phosphoproteins, and cell morphology from a single sample in one automated run. It opens the door to smart, scalable biology—shifting the field to high-resolution, high-value insights at unprecedented speed,” said Michael Previte, Co-founder and Chief Technology Officer of Element Biosciences.
New research from the AVITI24 platform, including abstracts and workshop sessions, will be presented at the American Association for Cancer Research (AACR) annual meeting in Chicago from April 25-30. Attendees can meet the Element team at Booth #4035 and Meeting Room MR-119.
Source – BusinessWire
Related Posts
Recent Posts
Scientists identify the neuroblastoma cells that signal poor outcomes
GARAGE improves rare cell detection in single-cell RNA sequencing analysis using AI
Machine learning reveals how RNA splicing is regulated in individual cell types
Illumina releases SpliceAI2 to help advance rare disease research
Postdoctoral Fellow – Long-Read RNA Methods Development for Neurodegeneration
Novel biosensor uses DNA ‘barcodes’ to uncover disease signals in cells
RNA-Seq Products & Services
Stay Connected